A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1756-9966
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells ; volume:38 ; number:1 ; day:14 ; month:8 ; year:2019 ; pages:1-16 ; date:12.2019
Journal of experimental & clinical cancer research ; 38, Heft 1 (14.8.2019), 1-16, 12.2019

Creator
Yu, Shengnan
Zhang, Jing
Yan, Yongxiang
Yao, Xudong
Fang, Lijuan
Xiong, Hui
Liu, Yang
Chu, Qian
Zhou, Pengfei
Wu, Kongming
Contributor
SpringerLink (Online service)

DOI
10.1186/s13046-019-1354-1
URN
urn:nbn:de:101:1-2020010105023879720605
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:51 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Yu, Shengnan
  • Zhang, Jing
  • Yan, Yongxiang
  • Yao, Xudong
  • Fang, Lijuan
  • Xiong, Hui
  • Liu, Yang
  • Chu, Qian
  • Zhou, Pengfei
  • Wu, Kongming
  • SpringerLink (Online service)

Other Objects (12)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis

Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte

Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte

PYK2 promotes HER2-positive breast cancer invasion

PYK2 promotes HER2-positive breast cancer invasion

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

How We Treat HER2-Positive Metastatic Breast Cancer

How We Treat HER2-Positive Metastatic Breast Cancer

Nanotechnology approaches to addressing HER2-positive breast cancer

Nanotechnology approaches to addressing HER2-positive breast cancer

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer

Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer

Related objects